Skip to main content
Evidence Snapshot

Free fatty acid receptor 4

CHEMBL5339 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5339
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Free fatty acid receptor 4 as ChEMBL target CHEMBL5339, mapped to UniProt Q5NUL3. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Free fatty acid receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5339
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q5NUL3
Free fatty acid receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Free fatty acid receptor 4 matters

As of 2026-09-13

Free fatty acid receptor 4 is reviewed as Free fatty acid receptor 4 (UniProt Q5NUL3); the current evidence base includes 5 approved drugs, 2157 compounds, and 119 assays, with lead potency reaching pChEMBL 8.3.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 2157 compounds, and 119 assays for this target. The dominant activity type is EC50. CHEMBL3952043 is the current potency anchor at pChEMBL 8.3.

Use CHEMBL3952043 as the tractability anchor when discussing potency (pChEMBL 8.3).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 8.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Free fatty acid receptor 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q5NUL3, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2157
Total Compounds
119
Total Assays
5
Approved Drugs
IC50: 13.0, EC50: 1831.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3952043
 8.3 EC50 —
No preferred name
CHEMBL5286838
 8.3 EC50 —
No preferred name
CHEMBL3972870
 8.2 EC50 —
No preferred name
CHEMBL2386353
 8.2 EC50 —
No preferred name
CHEMBL4637969
 8.2 EC50 —

Approved Drugs

Structure Compound First Approval
LOPERAMIDE HYDROCHLORIDE
CHEMBL1707
 1976
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:20Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5339